3 high-quality shares for smart investors

It would be fair to say that many share market investors would be pretty disappointed with the performance of the S&P/ASX 200 (Index: ^AXJO) (ASX:XJO) over the past 12 months, especially when compared to the double-digit returns that have been generated from the property market.

Instead of dwelling on the past however, I think investors should remain enthusiastic and focus on shares that have the ability to climb higher independently of the broader market.

With that in mind, here are three shares that investors might want to take a closer look at:

Bellamy’s Australia Ltd (ASX: BAL)

Despite presenting a pretty upbeat outlook at its AGM recently, shares of Bellamy’s have fallen more than 15% in the space of five trading sessions.

Most of this decline can be attributed to Bega Cheese Ltd’s (ASX: BGA) recent update that claimed the infant formula market is currently over-supplied. The report also implied that Bellamy’s and other infant food manufactures have been discounting their products in an effort to move stock.

Although I wouldn’t be surprised to see further falls from here, I think investors should remain on high alert as the company’s long term growth prospects remain compelling.

Bapcor Ltd (ASX: BAP)

Bapcor shares have fallen around 20% since the middle of August as investors have had to digest a number of acquisitions and a $185 million capital raising. Some parts of the market are understandably worried about the integration risks involved with trying to manage so many new acquisitions, but I think this is likely to be a short-term phenomenon.

The company has an excellent track record of extracting synergies from acquisitions and operates in a market with very attractive fundamentals.

While I wouldn’t rush out to buy the shares immediately, I think investors need to be ready to pounce should the shares fall much further from here.

Sirtex Medical Limited (ASX: SRX)

Sirtex is not really a share for conservative investors, but could be considered by those investors who are happy to accept a higher level of risk in search for higher returns.

The biotechnology company is expecting to deliver another year of double-digit dose sales growth, although it appears as though the market may be waiting for the results from a number of key clinical trials before getting too excited. These results are expected to be released during the course of next year and positive results could provide a big tailwind for Sirtex moving forward.

If you are after something a little less risky that still has the ability to generate market-beating returns, then you might want to consider this share instead.

This "dirt cheap" company is growing like gangbusters, and trading on a fat dividend yield, FULLY FRANKED. With interest rates set to stay at these low levels for years to come, for income-hungry investors, including SMSFs, this ASX company could be the "Holy Grail" of dividend plays for 2016. Click here to gain access to this comprehensive FREE investment report, including the name of this fast growing ASX dividend share. No credit card required.

Motley Fool contributor Christopher Georges owns shares of Sirtex Medical Limited. The Motley Fool Australia owns shares of Bapcor and Bellamy's Australia. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.